drugset / Trial / NCT05569239

Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

NCT05569239

Phase 2 Active not recruiting 2850 enrolled Osivax
RandomizedParallel-groupDouble-blindPrevention

Summary

The present study will evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years.

Timeline

Start
2025-09-08
Primary completion
2026-05-29
Completion
2026-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject OVX836 Vaccine 480 ug Intramuscular

Indications